OncoSec Medical Incorporated · OTC:ONCSQ
OncoSec Medical — Investor Presentation (March 2016)
28 slides from OncoSec Medical's investor presentation, March 2016
Slide 1: Arming the Immune System to Fight Cancer
ON C OS E C TM ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS0
Slide 2: Forward Looking Statements
Forward Looking Statements Our commentary and responses to your questions may contain forward looking statements, as described in the Private Securities Litigation Reform Act of 1995. These include comments concerning clinical trials and product development programs, evaluation of potential opportun
Slide 3: OncoSec's Platform Solution
OncoSec’s Platform Solution Addressing the Problem of Tumor-Induced Immune Subversion To unleash an anti-tumor immune response, OncoSec’s task is to shift the balance so that the immune drivers outweigh the brakes, so the immune system has the upper hand. CTLA-4 CD80 IL-12 CTLA-4 IL-12 CD80 Tumor PD
Slide 4: OncoSec Company Overview
OncoSec Company Overview Advancing a Leading Portfolio of Gene Therapies for Cancer Why Are We Different? ¡ Intratumoral immunotherapy: designed to deliver DNA-based therapeutics ¡ Platform focused on reversing the immuno-suppressive tumor microenvironment ¡ Capable of delivering multiple immune
Slide 5: Core Technology: ImmunoPulse
Core Technology: ImmunoPulse™ Overcoming Tumor Immune Tolerance via Intratumoral Immunotherapy ¡ Trains immune system to target and attack cancer ¡ Local delivery targets tumors directly triggering a systemic (abscopal) response with limited systemic exposure ¡ Ability to deliver a wide-variety o
Slide 6: ImmunoPulse IL-12
ImmunoPulse™ IL-12 Local Delivery Triggers Systemic Anti-Tumor Immune Response ¡ Uses DNA-encoded interleukin-12 ¡ Delivered directly to tumor in vivo; (IL-12), a potent pro-inflammatory stimulates local immune response, cytokine and subsequently, systemic effect ① Injection of ② Intratumoral ③ IL
Slide 7: Preclinical and Clinical Proof-of-Principle
PRECLINICAL AND CLINICAL PROOF-OF-PRINCIPLE Local Intratumoral Therapy Leads to Increased TILs & Tumor-Specific Systemic Response 6
Slide 8: The Unmet Medical Need of Low-TIL Tumors
The Unmet Medical Need of Low-TIL Tumors Driving Immunogenicity to Overcome Anti-PD-1 Non-Response PD-1 PD-L1 PD-1 x PD-L1 Response ImmunoPulse™ IL-12 Progress Adapted from Tumeh-PC, Nature. 2014 Nov 26; 515(7528): PD-1 blockade induces 7 responses by inhibiting adaptive immune resistance
Slide 9: Anti-PD-1 Non-Responders Constitute Majority of Patients
Anti-PD-1 Non-Responders Constitute Majority of Patients ¡ Anti-PD-1 can re-invigorate Anti-PD-1/PD-L1 mAB Tumor Type Non-Response ‘exhausted’ T cells, allowing them to attack and kill Melanoma ~ 60 – 80% immunogenic tumor cells Triple Negative ¡ However, checkpoint inhibitors ~70 – 82% 1 Breast a
Slide 10: Distant Tumor Effect in B16 Melanoma Tumor Model
Distant Tumor Effect in B16 Melanoma Tumor Model Primary Tumor Response Contralateral Tumor Response A. B. ¡ ImmunoPulse™ IL-12 leads to regression of treated tumor ¡ ImmunoPulse™ IL-12 significantly reduces growth of untreated (contralateral) tumors ¡ ImmunoPulse™ IL-12 monotherapy è range of ~
Slide 11: Tumor-Specific Neo-Antigen Response in B16-OVA Melanoma
Tumor-Specific Neo-Antigen Response Following Treatment in B16-OVA Melanoma A. Untreated B. IT-pIL12-EP C. % SIINFEKL tetramer+ SIINFEKL+ tetramer SIINFEKL+ tetramer Untreated IT-‐pIL12-‐EP CD44 CD44 ¡ The untreated B16-OVA mice failed to demonstrate a significant expansion of SIINFEKL+ CD8 T cel
Slide 12: Phase II Merkel Cell Carcinoma Data
Phase II Merkel Cell Carcinoma Data ImmunoPulse™ IL-12 Can Drive Antigen-Specific CD8+ T Cells in Patients 3 months Immediately Negative Control Pre-treatment Pre-treatment Pre-treatment MCC-specific tetramer +2 weeks +8 months +10 months Distant Post-treatment Lesion CD8 11
Slide 13: Phase II Metastatic Melanoma Data
Phase II Metastatic Melanoma Data Drives Local and Systemic Anti-Cancer Immune Response Best Overall Complete Patients with regression Disease Response Rate* Response Rate* of at least one non- Control treated lesion Rate* COMPLETE RESPONSE: Pre-Treatment Treated Scalp Lesions - Day 180 12
Slide 14: ImmunoPulse IL-12 Can Increase TILs
ImmunoPulse™ IL-12 Can Increase TILs Critical Priming of Tumors for Response to Checkpoint Inhibitors ImmunoPulse™ IL-12 can convert T cell poor tumors to T cell rich tumors, which are more likely to respond to anti-PD-1 therapies Metastatic Melanoma Merkel Cell Carcinoma Pre-ImmunoPulse IL-12 Post-
Slide 15: Rationale for Combination of ImmunoPulse IL-12 and Anti-PD-1 Blockade
Rationale for Combination of ImmunoPulseTM IL- 12 and Anti-PD-1 Blockade Hypothesis: Activation of the PD-1 checkpoint in distant, untreated tumors blunts the effectiveness of TILs generated by ImmunoPulseTM IL-12 PD-1 Blockade CONFIDENTIAL 14
Slide 16: Beyond ImmunoPulse IL-12: Targeting Multiple Facets of Tumor Immune Subversion
Beyond ImmunoPulseTM IL-12: Targeting Multiple Facets of Tumor Immune Subversion ④ Trafficking and T- ⑤ Infiltration of T-cell cell to Tumors into Tumors CX3CL1 CXCL9 LFA1/ICAM1 CXCL10 CCL5 VEGF Endothelin B receptor ③ Priming and ⑥ Recognition of T- Activation cell into Tumors CD28 CD137 T-cell rec
Slide 17: Building a Unique Immuno-Oncology Platform
BUILDING A UNIQUE IMMUNO-ONCOLOGY PLATFORM 16
Slide 18: What Have We Done So Far?
What Have We Done So Far? Realizing the Promise of Intratumoral Immunotherapy ¡ Positive multi-center Phase II clinical data in melanoma ¡ Positive Phase II data in Merkel cell carcinoma ¡ Clinical proof-of-concept of platform feasibility ¡ IL-12 drives tumor-specific CD-8 and abscopal responses
Slide 19: A Market Primed for Significant Growth
A Market Primed for Significant Growth Addressing a Great Unmet Medical Need in Oncology Percentage of Projected market value of Patients with solid tumors cancer checkpoint therapies, such that will not respond to immunotherapy as anti-PD-1 treatments checkpoint therapies treatment regimens alone e
Slide 20: Core Clinical Pipeline
Core Clinical Pipeline Aligned to Pursue Combination Approaches PHASE I PHASE II PHASE III Metastatic Melanoma Melanoma Combination Study IL12 + Anti-PD1 (KEYTRUDA®) Triple Negative Breast Cancer Orange = Monotherapy with IL-12 | Green = Combination Therapy 19
Slide 21: Phase II Metastatic Melanoma Combination Study
Phase II Metastatic Melanoma Combination Study RATIONALE COLLABORATORS ¡ Tumors need TILs for patients to respond to anti-PD-1 therapies ¡ Priming tumor microenvironment with IL-12 and promoting T-cell recruitment may enhance response to KEYTRUDA (pembrolizumab) OBJECTIVES ¡ Assess safety and eff
Slide 22: Pilot Triple Negative Breast Cancer (TNBC) Study
Pilot Triple Negative Breast Cancer (TNBC) Study RATIONALE COLLABORATORS ¡ Response rates to checkpoint therapies in pre-selected TNBC population were only 18 to 33% in preliminary reports ¡ ImmunoPulse™ IL-12 may drive an inflammatory response in TNBC patients, increasing response to anti-PD-1 th
Slide 23: Preclinical Industry Collaborations
Preclinical Industry Collaborations Driving Business and Development Efforts to Generate Greater Value Evaluating efficacy of ImmunoPulse™ and Heat Biologics’ ImPACT platform Developing biomarker tests to evaluate patient’s immune response to cancer Evaluating combination of ImmunoPulse™ IL-12 and P
Slide 24: Clinical and Commercialization Strategy
Clinical and Commercialization Strategy Multiple Combination Therapy Products COMBINATION THERAPIES WITH PARTNERS ¡ Combine OncoSec neoantigen-generating immunotherapies with third party checkpoint inhibitors or other immuno-oncology products COMBINATION THERAPIES IN-HOUSE USING DNA-BASED IMMUNOTHE
Slide 25: Development Milestones
Development Milestones Key Value Drivers Over the Next 12 Months Announce new key academic or industry collaborations Expand POC Phase II melanoma combo study sites, complete enrollment and present preliminary clinical data Complete TNBC biomarker study as POC in breast cancer, present interim data
Slide 26: OncoSec Management Team
OncoSec Management Team Experienced Leadership Team Punit Dhillon Chief Executive Officer David Meininger, PhD MBA Richard Slansky Senior VP, Business Chief Finance Officer Development Joann Lofgren, MBA Robert H. Pierce, MD VP, Market Development Chief Science Officer Sheela Mohan-Peterson Tu Diep
Slide 27: Financial Background
Financial Background Financial Runway to Achieve Critical Milestones NASDAQ ONCS Shares Outstanding 16.9M Market Cap $40M Cash Equivalents and Short-term $32M Investments Cash Runway Q1 2017 Debt $0 As of December 1, 2015 26
Slide 28: Thank You
THANK YOU NAS D AQ: ONCS SCAN THE CODE to download our complete Investor Overview www.OncoSec.com/ONCS-Investor-Package P | 855-662-6732 OncoSec Headquarters: E |[email protected] 5820 Nancy Ridge Drive W | www.oncosec.com San Diego, CA 92121 27